title: Beta-arrestin-biased parathyroid hormone ligands: a new approach to the development of agents that stimulate bone formation.
abstract: Because daily treatment with parathyroid hormone (PTH) increases bone mass and decreases fracture risk, physicians use this agent to treat osteoporosis. However, PTH stimulates both bone-forming and bone-resorbing cells, complicating its clinical use. New results show that, in mice, a so-called biased agonist (PTH-betaarr) that selectively activates beta-arrestin -dependent signaling leads to PTH-induced trabecular bone formation without a simultaneous increase in bone resorption. This targeted approach may pave the way for future pharmacological developments in the treatment of osteoporosis.
authors.affiliation: Service of Bone Diseases, World Health Organization Collaborating Center for Osteoporosis Prevention, Department of Rehabilitation and Geriatrics, Geneva University Hospital, Geneva, Switzerland.
authors.forename: Serge L
authors.initials: SL
authors.lastname: Ferrari
authors.forename: Mary L
authors.initials: ML
authors.lastname: Bouxsein
mesh_terms: D000818:Animals; D019390:Arrestins / Q000235:genetics / Q000378:metabolism*; D001846:Bone Development / Q000187:drug effects*; D005260:Female; D006801:Humans; D008024:Ligands; D008297:Male; D051379:Mice; D010281:Parathyroid Hormone / Q000378:metabolism*; D015398:Signal Transduction; D000071557:beta-Arrestins
chemical_list: D019390:Arrestins; D008024:Ligands; D010281:Parathyroid Hormone; D000071557:beta-Arrestins